Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round.
The funding will be used to advance the company’s pipeline of therapies to treat degenerative eye diseases, starting with age-related macular degeneration, according to a March 25 news release from the company.
Character Biosciences has partnered with more than 150 ophthalmology treatment centers across the U.S. to conduct observational trials.
The trails integrate genetics with longitudinal clinical and imaging data from more than 6,500 patients to discover therapeutic targets to treat AMD.
In addition, the company is planning to expand and study other ophthalmic diseases in the future.
The funding was co-led by new investors aMoon and Luma Group, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.